Ownership and insider activity for Benitec Biopharma Inc. (BNTC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Price
| Price | $11.04 |
| Market Cap | $379M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-29 | BUCHI J KEVIN | G-Gift | 51,813 | |
| 2026-05-26 | Friedman David Matthew | A-Award | 35,000 | $401K |
| 2026-05-22 | Friedman David Matthew | |||
| 2026-01-22 | Mates Sharon | A-Award | 31,500 | $404K |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 65,800 | $884K |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 14,320 | $188K |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 42,600 | $547K |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 11,587 | $156K |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 2,516 | $33K |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | P-Purchase | 7,400 | $95K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.4M | $16.2M | $22.5M | $9.8M | $19.8M | $4.1M | $2.5M | $50.9M | $97.7M | $180.0M |
| Short-term Investments | $76845 | $22037 | $1430 | $1000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $3.5M | $4.3M | $5.2M | $59000 | $25000 | $3000 | $55000 | $229000 | $33000 | $4000 |
| Inventory | -$65065 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $22.2M | $21.0M | $26.8M | $10.8M | $20.6M | $4.8M | $3.7M | $51.7M | $98.5M | $181.7M |
| Property, Plant & Equipment | $341960 | $234334 | $469227 | $769000 | $577000 | $993000 | $613000 | $449000 | $991000 | $871000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $22.7M | $21.4M | $27.5M | $11.7M | $21.4M | $6.0M | $4.5M | $52.2M | $99.6M | $182.6M |
| Accounts Payable | $133710 | $426063 | $1.5M | $282000 | $274000 | $422000 | $1.1M | $1.4M | $201000 | $913000 |
| Short-term Debt | 0 | 0 | 0 | $192000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $864506 | $2.6M | $2.6M | $1.1M | $1.4M | $2.5M | $4.0M | $4.9M | $1.8M | $5.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $266000 |
| Total Liabilities | $891402 | $2.6M | $2.6M | $1.5M | $1.4M | $3.1M | $4.3M | $5.0M | $2.3M | $5.6M |
| Retained Earnings | -$136.2M | -$107.9M | -$108.9M | -$116.6M | -$130.1M | -$148.3M | -$167.9M | -$190.3M | -$228.2M | -$273.7M |
| Total Equity | $21.6M | $13.8M | $16.6M | $10.2M | $20.0M | $2.9M | $202000 | $47.2M | $97.3M | $177.0M |
| Total Debt | 0 | 0 | 0 | $405000 | $213000 | $811000 | $559000 | $284000 | $849000 | $762000 |
| Net Debt | -$17.4M | -$16.2M | -$22.5M | -$9.4M | -$19.6M | -$3.3M | -$1.9M | -$50.6M | -$96.9M | -$179.2M |
| Working Capital | $21.4M | $18.4M | $24.2M | $9.7M | $19.2M | $2.3M | -$249000 | $46.8M | $96.7M | $176.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 56.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 107.24 |
Profitability
| Return on Equity | -34.82% |
| Return on Invested Capital | -29.28% |
| Return on Assets | -26.14% |
| Gross Margin | -14.21% |
| Operating Margin | -9701.08% |
| Net Margin | -8792.09% |
Related companies: AUTL · GALT · IMAB · LCTX · NGNE · OCGN · PRTC
Explore sector: Healthcare · Biotechnology
More sections of BNTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks